AG
CRBP icon

Advisor Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Advisor Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$38K Buy
231
+11
+5% +$1.63K ﹤0.01% 3589
2019
Q3 		$32K Sell
220
-8
-4% -$1.39K ﹤0.01% 3688
2019
Q2 		$48K Buy
228
+6
+3% +$1.28K ﹤0.01% 3389
2019
Q1 		$46K Buy
222
+7
+3% +$1.54K ﹤0.01% 3452
2018
Q4 		$37K Sell
215
-8
-4% -$1.6K ﹤0.01% 3399
2018
Q3 		$51K Buy
223
+18
+9% +$2.91K ﹤0.01% 3270
2018
Q2 		$32K Sell
205
-35
-15% -$6.36K ﹤0.01% 3414
2018
Q1 		$43K Buy
240
+83
+53% +$18.6K ﹤0.01% 3175
2017
Q4 		$33K Buy
157
+25
+19% +$5.35K ﹤0.01% 3369
2017
Q3 		$28K Sell
132
-6
-4% -$1.17K ﹤0.01% 3359
2017
Q2 		$26K Hold
138
– – ﹤0.01% 3318
2017
Q1 		$35K Buy
138
+38
+38% +$9.33K ﹤0.01% 2974
2016
Q4 		$25K Hold
100
– – ﹤0.01% 3081
2016
Q3 		$20K Buy
100
+33
+49% +$4.11K ﹤0.01% 3136
2016
Q2 		$5K Buy
+67
New +$5.25K ﹤0.01% 3771

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Advisor Group's CRBP Position: Q4 2019 in Review

Advisor Group increased its Corbus Pharmaceuticals (CRBP) stake by 5% in Q4 2019, buying an estimated $1.63K and bringing the position to 231 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #3589.

Advisor Group first reported a position in CRBP in Q2 2016 and has held it in 15 quarters since. The position peaked at $51K in Q3 2018. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

  • Advisor Group held 231 shares of Corbus Pharmaceuticals worth $38K as of Q4 2019.
  • Advisor Group bought 11 Corbus Pharmaceuticals shares in Q4 2019, an estimated $1.63K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3589 holding.
  • Advisor Group first reported a position in Corbus Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Advisor Group's Corbus Pharmaceuticals position peaked at $51K in Q3 2018.
  • 105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.